Healthcare | November 07, 2024
KIMS to acquire 3,000 beds in next 5 years in Kerala
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Subscribe To Our Newsletter & Stay Updated
